Clinical trials: Depressive Symptoms
Depressive Disorder
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- Orvepitant MDD (NCT00880048)
- Testing
- orvepitant
- Where
- 32 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Depression, Depression, Postpartum
TrueBlue Clinical Study - Investigating the Use of a Mobile Phone App TrueBlue for Monitoring Depression and Anxiety
This trial will assess the safety, feasibility, acceptability, usability and agreement with validated scales of an automated mood monitoring App (TrueBlue), in adult, perinatal participants (recruited between 12 weeks of…
- Conditions
- Depression, Depression, Postpartum, Anxiety in Pregnancy, Anxiety
- Trial name
- NCT06364488
- Testing
- TrueBlue App
- Where
- 2 sites in United Kingdom
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- BlueSkeye AI
Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Trial name
- NCT07772531
- Testing
- BMS-986511
- Where
- 27 sites in United States, Czechia
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Depressive Disorder, Major
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate sustained release (DVS SR) in subjects with major depressive disorder.
- Trial name
- NCT00445679
- Testing
- DVS SR, Paroxetine
- Where
- 43 sites in China, India and 2 more
- Volunteers
- 807 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
- Trial name
- NCT06126497
- Testing
- Ropanicant
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
An Open-Label Study of Azetukalner in Major Depressive Disorder
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of…
- Trial name
- X-NOVA-OLE (NCT06922110)
- Testing
- Azetukalner
- Where
- 71 sites in United States, Finland and 1 more
- Volunteers
- 460 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Anxiety, Depressive Symptoms
Efficacy of Digital Problem Solving Application in Reduction of Anxiety, Depression and Substance Use Disorder Symptoms
The focus of this study is the impact of usage of a mobile application to support problem-solving therapy on symptoms of anxiety, depression and substance use.
- Conditions
- Anxiety, Depressive Symptoms, Substance Use Disorders
- Trial name
- Efficacy (NCT06346431)
- Testing
- DSPT - Digital Support for Problem-solving Therapy
- Volunteers
- 100 people
- Sponsor
- 7 Generation Games
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07553130
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 785 people, healthy volunteers welcome
- Sponsor
- Accexible
Depression
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
- Trial name
- NCT03870776
- Testing
- MAP4343
- Where
- 10 sites in France
- Volunteers
- 126 people
- Sponsor
- Mapreg
Depression
Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of Psychiatric Electroencephalogram Registry (PEER) Interactive to inform medication prescription in subjects with a…
- Trial name
- SMART-MD (NCT02988076)
- Testing
- PEER Interactive Report
- Where
- United States
- Volunteers
- 468 people
- Sponsor
- MYnd Analytics
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bipolar Disorder, Depression
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I…
- Trial name
- NCT02670538
- Testing
- Cariprazine
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 493 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Depressive Disorder, Major
A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.
- Trial name
- NCT03352453
- Testing
- Rapastinel
- Where
- 17 sites in United States
- Volunteers
- 138 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Depressive Disorder, Major
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive…
- Trial name
- NCT04513912
- Testing
- Seltorexant, Quetiapine XR
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 757 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Major Depression, Dysthymia
Online System for Identifying and Addressing Teen Depression in Primary Care
A novel web-based module (Teen Depression Module or TDM)has been created for assisting primary care providers (PCPs) in screening for and addressing and referring teens with depression.
- Conditions
- Major Depression, Dysthymia, Depressive Symptoms
- Trial name
- Depression (NCT04489485)
- Testing
- Teen Depression Module used for care
- Where
- United States
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- Total Child Health, Inc.
Major Depressive Disorder
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
- Trial name
- EXTEND (NCT06605105)
- Testing
- CYB003
- Where
- 49 sites in United States, Australia and 3 more
- Volunteers
- 468 people
- Sponsor
- Cybin IRL Limited